Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Videos
Diagnostics
In Vitro Diagnostics
Return to: MDBR Home | Diagnostics | In Vitro Diagnostics

3D Signatures participates in clinical trial of prostate cancer

Published 20 October 2016

3D Signatures has announced that its participation in a major clinical trial for prostate cancer diagnosis and management known as PRECISE.

This trial marks the Company's first step toward validation and approval of clinical risk assessment tests for prostate cancer.

PRECISE (PRostate Evaluation for Clinically Important disease MRI vs Standard Evaluation procedures) is led by renowned uro-oncologist and prostate cancer thought leader, Dr. Laurence Klotz. Dr. Klotz is the Chairman of the Canadian Urology Research Consortium (the "CURC"), the study sponsor.

It is the first randomized, multicenter study focused on biopsy naive patients (approximately 450 men) with clinical suspicion of prostate cancer.

The 24-month prospective study is principally designed to compare cancer detection rates and monitoring efficacy of TRUS guided biopsy versus MRI targeted biopsy, two existing surgical tools employed in the diagnosis and monitoring of prostate cancer patients.

PRECISE will incorporate 3DS' blood-based tests into the original biopsy focused investigation as a correlative biomarker.

3DS' participation seeks to establish a baseline of genomic instability for prostate cancer patients, provide follow-up monitoring information and provide essential data for developing several blood-based clinical tests for personalized assessment and treatment of prostate cancer patients.

"The PRECISE trial aims to determine whether MRI, a non-invasive imaging test, can replace invasive prostate biopsies in men with an elevated PSA," said Principal Investigator, Dr. Klotz.

"We have an opportunity to test a new blood-based biomarker to accurately stratify patients into risk groups. If successful, this could represent a first-in-class blood test which would specifically identify clinically significant prostate cancer. Such a tool does not currently exist for prostate cancer patients."

Awarded by way of a rigorous peer review process run by Prostate Cancer Canada, this multimillion dollar project is funded by the Ontario Institute for Cancer Research (OICR) and the Movember Foundation Canada.

To support its participation in PRECISE and the development of related clinical tests, 3DS' projected budget is approximately $2.4M over a two-year period which represents at least 50% savings over an independently run study.



Source: Company Press Release